+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a prospective, observational study to assess asthma control, health-related quality of life HRQL, lung function, and medication use in patients with severe eosinophilic asthma who are treated with benralizumab under routine care in Germany. The study aims to observe how these patients manage their asthma over time and how their treatment impacts their daily lives and health status. Participants receive benralizumab as part of their standard care, with no experimental treatment assigned by the study. The study lasts up to 52 weeks and monitors changes in asthma control using tools like the Asthma Control Test ACT and the Asthma Impairment and Risk Questionnaire AIRQ. Health-related quality of life is measured at baseline and follow-ups using the mini Asthma Quality of Life Questionnaire miniAQLQ. Patients also keep a weekly diary of their asthma medication intake, either on paper or electronically, to track any changes. Throughout the study, participants will have assessments at various time points up to one year after starting benralizumab. These include questionnaires on asthma control and quality of life, lung function tests, and biomarker measurements such as eosinophil levels and exhaled nitric oxide. Researchers analyze changes in medication doses and asthma symptoms, while patients regularly report their experiences. The study focuses on real-world outcomes without altering prescribed treatments, aiming to provide insights into the effects of benralizumab in everyday clinical practice.

Age: 18Years - 120YearsAll Genders
41 locations
G

Actively Recruiting

Researchers are evaluating clinical outcomes in patients with difficult to treat depression, including those with treatment resistant depression, who receive Vagus Nerve Stimulation VNS Therapy as an additional treatment. The study focuses on patients diagnosed with unipolar or bipolar disorder with chronic or recurrent depression who have not responded well to standard psychiatric care. Diagnosis and comorbid conditions are confirmed using the Mini International Neuropsychiatric Interview MINI. Participants will be implanted with a VNS Therapy System, which includes an implantable generator, lead, and external programming system. The study plans to enroll at least 500 patients across up to 80 sites globally. Each participant will have a baseline visit 1 to 6 weeks before the implant procedure. After implantation, participants will be followed for a period ranging from 36 to 60 months, with the study concluding once the last patient completes 36 months of follow-up. During the study, participants will attend outpatient clinic visits to complete evaluations based on the study protocol. Researchers will measure changes in depression symptoms using the Montgomery sberg Depression Rating Scale MADRS at 12 months as the primary outcome. Secondary outcomes include changes in mood, quality of life, function, suicidality, cognition, anxiety, and treatment adjustments, monitored for an average of 4 years. Safety and tolerability will also be assessed through tracking adverse events.

Age: 18Years +All Genders
18 locations
S

Actively Recruiting

Researchers are studying metastatic colorectal carcinoma mCRC patients who have a specific BRAFV600E mutation, which is linked to poorer outcomes compared to those without it. This mutation leads to shorter survival times after initial treatments, prompting the need for new therapy combinations. This research aims to observe how the drugs encorafenib and cetuximab work together in real-world settings for patients who have already received prior systemic therapies. This non-interventional, prospective, longitudinal study focuses on patients treated with encorafenib plus cetuximab following prior systemic therapy. The study collects data on treatment effectiveness, safety, and quality of life among a broader patient population in Germany, Austria, and Switzerland. Patients may have started treatment up to three months before joining the study or plan to start soon, and the study observes their outcomes without influencing treatment decisions. Participants will be monitored through data collection on their disease and treatment profiles, including patient and physician assessments, adverse events, and treatment details. The main outcome measured is overall survival at 12 months after starting treatment. Additional information gathered includes treatment duration, dose intensity, interruptions, and patient-reported quality of life using questionnaires. Safety and tolerability are also evaluated throughout treatment, with follow-up averaging nine months.

Age: 18Years +All Genders
70 locations
O

Actively Recruiting

Researchers are evaluating how well Fruquintinib works to treat adults with metastatic colorectal cancer who have already received standard treatments. This observational study in Germany aims to analyze patient response to Fruquintinib in routine clinical practice, focusing on survival, safety, medical care usage, and quality of life. The study also includes a translational research project to link clinical data with biomarkers for better understanding treatment benefit. Participants receive Fruquintinib as determined by their treating physician according to approved guidelines. The study collects real-world data from about 150 patients across various healthcare settings. Archival tumor tissue and blood samples are gathered to study biomarkers and circulating tumor DNA, which may indicate treatment response. During the study, participants health and treatment effects are monitored through clinical data and biomarker analysis. Researchers measure disease control, response rates, survival, adverse events, quality of life, treatment duration, hospitalizations, and other outcomes up to 33 months. The study provides insight into Fruquintinibs use and impact in everyday care over an average of 6 to 7 months of treatment and extended follow-up.

Age: 18Years +All Genders
42 locations
E

Actively Recruiting

Researchers are evaluating the impact of standardized patient coaching on how consistently patients with hormone receptor-positive, HER2-negative early breast cancer take abemaciclib, a prescribed oral therapy. The study aims to find out if coaching based on a recognized teaching tool improves treatment adherence compared to routine care. Participants will provide information through several questionnaires to help answer this question. Participants receive standardized coaching based on the Multinational Association of Supportive Care in Cancer MASCC Oral Agent Teaching Tool MOATT. The coaching is designed to support patients while they take abemaciclib combined with endocrine therapy. The study follows patients for up to one year or until they stop taking abemaciclib permanently, whichever comes first. During the study, participants will complete questionnaires measuring their satisfaction with medicine information, medication adherence, and patient typology at 6 and 12 months after starting therapy. Researchers will monitor the time until patients discontinue abemaciclib as the main outcome. The study includes ongoing assessments to understand how coaching affects treatment persistence and patient experience over the year-long period.

All AgesFEMALEPhase Not Applicable
8 locations
E

Actively Recruiting

Researchers are studying the safety and effectiveness of long-term peritoneal dialysis PD catheters developed by Fresenius Medical Care in both adult and pediatric patients with renal insufficiency. The study focuses on patients treated with continuous ambulatory peritoneal dialysis CAPD or automated peritoneal dialysis APD, assessing how well the catheters perform and their impact on PD treatment outcomes such as peritoneal clearance and ultrafiltration. Participants will be patients who are either starting PD with the Fresenius catheters or have begun PD within the last 18 months. The study observes their treatment over time without introducing new interventions. Data on safety and performance will be collected approximately every six months, following each centers practice, to monitor the catheters function and patient outcomes. During the study, participants will have assessments every six months plus or minus two months to review safety and performance variables related to the PD catheters and treatment results. These evaluations include monitoring peritoneal clearance and ultrafiltration. The study aims to gather long-term data up to the planned completion in December 2029, helping to understand the catheters safety profile and efficacy during extended use.

All AgesAll Genders
2 locations
P

Actively Recruiting

Researchers are conducting a prospective registry study to observe and document the treatment and disease progression in patients with recurrent and metastatic prostate cancer. The study includes four distinct patient groups based on disease status those with biochemical recurrence after local treatment, non-metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer. Each group is enrolled and followed independently over different time periods to understand the course of therapy and disease. The study does not prescribe any specific treatment but records routine care as decided by each patients physician. Data collection occurs during routine clinical visits at set intervals, including after enrollment, every 3 to 6 months, and when therapy changes occur. Standardized quality of life questionnaires FACT-P and EQ-5D-5L are completed, and biological samples are collected to support comprehensive assessment. Participants are followed long-term, with an average follow-up of seven years. Researchers document therapy patterns, disease management strategies, imaging assessments, patient-reported outcomes, treatment adherence, and adverse events throughout this period. The focus is on real-world data reflecting everyday clinical practice, enabling a detailed understanding of treatment effectiveness and disease progression in prostate cancer patients.

Age: 18Years +MALE
53 locations
O

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a subcutaneous treatment using one cycle of cladribine for patients with hairy cell leukemia who need treatment. This study focuses on patients who are either untreated or have been previously treated only with alpha-interferon. The goal is to determine the rate of complete remission and to assess whether a second cycle of treatment benefits those with a non-optimal response, defined as detectable residual disease or partial remission four months after the initial treatment. Participants receive cladribine at a dose of 0.14 mgkg body weight administered subcutaneously as a bolus injection once daily for five consecutive days. After four months, remission status is evaluated. Patients showing non-optimal response may be considered for a second treatment cycle. This phase 23 trial is designed to optimize therapy for hairy cell leukemia by closely monitoring treatment response and toxicity. During the study, participants undergo evaluations including disease status assessment through bone marrow and blood tests, with a focus on remission rates four months post-treatment. Researchers track complete remission rates and monitor for residual disease. Safety is also monitored by assessing potential toxicities. Participants general health status and other laboratory tests are reviewed to ensure eligibility and ongoing suitability for treatment throughout the study period, which spans several months with follow-up assessments.

Age: 18Years - 90YearsAll GendersPhase 2Phase 3
76 locations